Growth Drivers and Opportunities for Biomarkers in Healthcare
“Growth Drivers and Opportunities for Biomarkers in
24th September 2014
Global biomarkers market expected to exceed $40 billion by 2018 driven by
Genomics: CAGR of 26.9%
Imaging: CAGR of 14.8%
Proteomics: CAGR of 13.5%
Bioinformatics: CAGR of 19.3%
CAGR from 2013-2018
Biomarkers – How Important are they?
Identifying subgroups of patients (e.g. patient sub-groups, optimized patient
Understanding pathways and mechanisms
Improved decision making in R&D (e.g. tools for profiling targets, compounds)
Drivers for pharmaco-diagnostic development (e.g. increased benefit/ risk ratio,
Biomarkers support navigation throughout the entire lifecycle of a medicine -
from target identification to market
Biomarkers are useful throughout the lifecycle of a medicine from target
identification to commercialization
Industry: Pharma and DiagnosticsAcademic: CROs
• ‘Omics’ technologies
o Others: Glycomics, Lipidomics
• Imaging technologies
• Drug discovery and
• Molecular diagnostics
• Personalised medicine
• Cardiovascular diseases
• Neurological disorders
• Autoimmune disorders
• Infectious diseases
Total Biomarkers Market in Drug Discovery and Development: Market Overview, Global, 2013
Key Stakeholders in Biomarker industry
Part-Takers in Personalised
medicine- Biomarker pie
Patients Increases effectiveness
Doctors Increases safety in
Better outcome at lower
Technology Lifecycle Analysis
Total Biomarkers Market in Drug Discovery and Development: Technology Lifecycle Analysis,
MaturityDevelopment Growth Decline
Note: Bubble size represents market size;
Drug Discovery (Lead discovery/Optimization): A number of new targets can be identified using
biomarkers. Use of metabolomics and glycomics approaches are paving way for target
identification, mainly for cancers and autoimmune diseases. Based on biomarker signatures,
targeted personalized therapies can be developed. Biomarkers have enabled launch of many
biologics that include Herceptin, Gleevec, Iressa, and Enbrel.
Pre-Clinical/Clinical Development: Identification of biomarkers that can be used as markers for
response to therapy, and used in clinical trials, thus bringing down the costs and time of clinical
trials. Prediction and detection of toxicity, efficacy in pre-clinical or clinical setting is easy with the
use of biomarkers. Based on toxicities and efficacy levels, patient stratification is easier.
Clinical Management: Monitoring response to therapy (companion diagnostics) and Phase 4
(post marketing surveillance) can be regularized with the use of biomarkers. Changes in dose,
drug type, and management of ADEs will be possible.
Diagnostics/Screening: Disease detection at early stages and screening for high-risk individuals
. Overall reduction in healthcare costs with regular biomarker-based diagnostics.
Critical unmet needs and potential game-changing strategies
Critical Unmet Need Potential Game-changing Strategy
There is a need for a
collaborative model that will
enable companies to self-
finance the demonstration of
clinical utility and bring products
to the market on time.
• Collaboration with Pharmaceutical Companies
• Marketing Direct-to-consumer (DTC) Stand-alone
As no specific drug is involved
in the development of
diagnostic tests, diagnostic
companies market these tests
to healthcare providers directly.
• Integration Model from Research to Commercialisation
• Receive incentives for research and royalties, ranging from 2
to 3% on marketed products.
• The second type is a combination of technology licensing
and the demonstration of economic benefits.
• The third type is a fully integrated stand-alone company
Total Biomarker Market in Drug Discovery and Development: Game-changing Strategies,
Defining Future Healthcare Trends for Biomarkers
Biomarkers will find extensive demand in patient stratification applications,
particularly for cardiac and neurological disorders.
An integrated systems biology approach for information analysis for
biomarker discovery will be the key area of focus in future.
Evolving biomarkers will bring a paradigm shift in the way healthcare is
provided - from the mere identification of drug targets to the optimisation of
(+60) 3 6204 5910
Dr Siddharth Dutta
Healthcare & Life Sciences
(+60) 3 6204 5842
Global Program Manager – Life
+1 (650) 475 4560
(+65) 6890 0986